Weekly Recap | Beigene +2.32%, Tevimbra combination survival data lands
I'm LongbridgeAI, I can summarize articles.Beigene (ONC) gained 2.32% this week to close at $377.63, up from $369.06 the previous Friday. The S&P 500 fell 0.47% over the same stretch, leaving the stock about 2.79 percentage points ahead of the benchmark. The week opened weakly at $371.53 and printed an intraweek low of $368.51 on Monday, then rallied hard on Tuesday and Wednesday. Wednesday marked the high at $388.66 before easing, and Friday saw a pullback from an open of $384.40 to an intraday low of $372.
The Week
Beigene (ONC) gained 2.32% this week to close at $377.63, up from $369.06 the previous Friday. The S&P 500 fell 0.47% over the same stretch, leaving the stock about 2.79 percentage points ahead of the benchmark. The week opened weakly at $371.53 and printed an intraweek low of $368.51 on Monday, then rallied hard on Tuesday and Wednesday. Wednesday marked the high at $388.66 before easing, and Friday saw a pullback from an open of $384.40 to an intraday low of $372.65, finishing at $377.63.
Key Events
Clinical news around gastric and gastroesophageal cancers dominated the week. On Friday, BeOne Medicines said its Tevimbra combination extended median survival to 27 months in a gastroesophageal cancer trial, and it reported sustained overall survival benefit from a Phase 3 HER2+ gastric cancer trial. Earlier in the week, the company said it would present Phase 1 liver cancer drug data at ESMO 2026. Beigene also confirmed it will report third-quarter 2026 results before the open on 5 November; the market is looking for EPS of $1.9058 and revenue of $1.758 billion. The shares dipped 8.69% pre-market on Tuesday, hit a 52-week high on Wednesday, and slipped again on Friday.
Analyst Ratings
Of 27 institutions covering the stock, 19 rate it buy, 7 rate it overweight, and 1 rates it hold, with no underweight or sell ratings. The consensus rating is strong buy, and the consensus target price of $436.46 implies about 15.58% upside from the current price. Targets range from $370 to $528, so the spread is wide. Beigene ranks 11th within the biotech industry group, where 511 names are covered.
The Week Ahead
A heavy macro slate starts with Dallas Fed manufacturing activity on Monday. Tuesday brings durable goods orders, FHFA house prices, Case Shiller home-price data, new home sales, the Richmond Fed composite, and consumer confidence. On the company side, third-quarter 2026 results land before the open on 5 November, with estimates at EPS of $1.9058 and revenue of $1.758 billion. The question is whether this week’s clinical momentum shows up in the operating numbers.
In Short
This week paired positive clinical data with a mostly upbeat rating picture: the Tevimbra survival read strengthened the pipeline narrative, the consensus rating is strong buy, and the target sits above spot. At the same time, the stock pulled back after touching a 52-week high, and the latest session’s fund-flow snapshot showed small-lot net buying alongside a split between medium and large lots. The next check is whether third-quarter results can carry the momentum, and how valuation and money flows converge from here.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.